Washington: Federal health officials expressed concern early Tuesday over AstraZeneca’s inclusion of “outdated information” in the efficacy results of its COVID-19 vaccine’s late-stage U.S. trial.
In a rare statement, the National Institute of Allergy and Infectious Diseases said the information in question “may have provided an incomplete view of the efficacy data” concerning the company’s two-dose vaccine regimen.
“We urge the company to work with the [Data and Safety Monitoring Board] to review the efficacy data and ensure the most accurate and up-to-date efficacy data be made public as quickly as possible,” the guidance said.
The statement was issued a day after AstraZeneca publicized results of its long-awaited late-stage U.S. trial of vaccine candidate AZD1222 that showed it had a 79% efficacy against symptomatic infection and 100% efficacy against severe disease and hospitalizations.
